Matches in Wikidata for { <http://www.wikidata.org/entity/Q85909957> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q85909957 description "artikull shkencor i botuar më 01 shkurt 2015" @default.
- Q85909957 description "artículu científicu espublizáu en febreru de 2015" @default.
- Q85909957 description "im Februar 2015 veröffentlichter wissenschaftlicher Artikel" @default.
- Q85909957 description "scientific article published on 01 February 2015" @default.
- Q85909957 description "wetenschappelijk artikel" @default.
- Q85909957 description "наукова стаття, опублікована в лютому 2015" @default.
- Q85909957 name "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 name "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 name "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 type Item @default.
- Q85909957 label "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 label "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 label "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 prefLabel "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 prefLabel "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 prefLabel "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 P1433 Q85909957-44054062-C687-437C-807D-68E298B2EFEE @default.
- Q85909957 P1476 Q85909957-8C09D022-9410-42DD-82DA-E3A36C4948C1 @default.
- Q85909957 P2093 Q85909957-068E1FC3-F2BF-445D-A41C-C793950F297F @default.
- Q85909957 P2093 Q85909957-0ACBA9C6-4861-4D9D-83EF-7CE61B952ECB @default.
- Q85909957 P2093 Q85909957-12FDAACA-86CD-43C1-99E8-9B601EE3C836 @default.
- Q85909957 P2093 Q85909957-27E77692-5628-4E7E-A3FA-F904CA8BA832 @default.
- Q85909957 P2093 Q85909957-429AC08D-C746-42A1-AB84-6DF458F35873 @default.
- Q85909957 P2093 Q85909957-4CA42A96-E5F4-4F4B-A27E-AE5A21CF0DDF @default.
- Q85909957 P2093 Q85909957-50A108D3-29A3-4783-AFCE-B73B9323F4D6 @default.
- Q85909957 P2093 Q85909957-56A18747-96B5-4F04-9E86-8CC5BB8C39B0 @default.
- Q85909957 P2093 Q85909957-63EFEE98-260C-4C44-9714-9901023F7B64 @default.
- Q85909957 P2093 Q85909957-76AF0BEA-351C-4D58-8779-95D707E383DC @default.
- Q85909957 P2093 Q85909957-B4FB4C2B-B391-4D57-8904-831E06EA27DF @default.
- Q85909957 P2093 Q85909957-C08046DA-A5BD-4C98-95D3-650B2863147B @default.
- Q85909957 P2093 Q85909957-CCD441C3-DC17-467B-8AF4-44FBE5208CF6 @default.
- Q85909957 P2093 Q85909957-FDAEA1FB-C6EE-4ACB-8C68-E0FCDF28C51F @default.
- Q85909957 P304 Q85909957-56F2981B-7154-4B2F-8676-4CE5A1E996A7 @default.
- Q85909957 P31 Q85909957-1462E05D-266E-42A6-9997-9FFDFD1F98BA @default.
- Q85909957 P356 Q85909957-6E55FD67-E284-42D9-A4A8-21759E9A3116 @default.
- Q85909957 P433 Q85909957-DDD93D99-9C8A-4162-B350-CDA173D121D4 @default.
- Q85909957 P478 Q85909957-900893F0-4AF1-4A32-BC85-0B680625486C @default.
- Q85909957 P577 Q85909957-7CDDBBAA-9909-49FF-B58A-679ECDF10D39 @default.
- Q85909957 P698 Q85909957-B0E72BF8-9E29-4811-BEFB-B0542E47E229 @default.
- Q85909957 P356 IMJ.12621 @default.
- Q85909957 P698 25370691 @default.
- Q85909957 P1433 Q15749165 @default.
- Q85909957 P1476 "Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response" @default.
- Q85909957 P2093 "A Agarwal" @default.
- Q85909957 P2093 "A J Walsh" @default.
- Q85909957 P2093 "A Pudipeddi" @default.
- Q85909957 P2093 "A Sechi" @default.
- Q85909957 P2093 "AIBDA" @default.
- Q85909957 P2093 "B Headon" @default.
- Q85909957 P2093 "I C Lawrance" @default.
- Q85909957 P2093 "J M Andrews" @default.
- Q85909957 P2093 "L Beswick" @default.
- Q85909957 P2093 "M Sparrow" @default.
- Q85909957 P2093 "S Antoniades" @default.
- Q85909957 P2093 "S Connor" @default.
- Q85909957 P2093 "S Costello" @default.
- Q85909957 P2093 "S Ghaly" @default.
- Q85909957 P304 "170-177" @default.
- Q85909957 P31 Q13442814 @default.
- Q85909957 P356 "10.1111/IMJ.12621" @default.
- Q85909957 P433 "2" @default.
- Q85909957 P478 "45" @default.
- Q85909957 P577 "2015-02-01T00:00:00Z" @default.
- Q85909957 P698 "25370691" @default.